Pfizer is pulling further away from the gene therapy field with its decision to discontinue hemophilia product Beqvez. The New York pharma is ending global development and commercialization of ...

Pfizer CEO Dr. Albert Bourla and chair of the PhRMA Board of Directors Pharmaceutical Research and Manufacturers of America (PhRMA) Pfizer CEO Dr. Albert Bourla and chair of the PhRMA Board of ...

Pfizer stock has suffered as demand for the company’s top selling coronavirus products declined. The pharma giant has reached an important transition point. Right now, as an investor, you may be ...

Claims on social media suggest Pfizer's COVID vaccine has fatal side effects, referencing a US House document. However, the report includes adverse events, not side effects. Adverse events ...

Pfizer hopes a unique life-extension benefit for its Talzenna can serve to further expand the drug’s already broadest-in-class U.S. label in prostate cancer. Following an FDA approval in 2023 ...

Pfizer generated strong growth last year despite a significant drop in COVID revenue. The company's business is solid, and its growth prospects are encouraging. Investors, however, remain ...

The best of New York for free. Sign up for our email to enjoy New York without spending a thing (as well as some options when you’re feeling flush). Our newsletter hand-delivers the best bits to ...

After an apparent accidental early release, Pfizer has revealed phase 1 data showing its investigational candidate, alongside Xtandi, reduced prostate cancer progression by 49%. The data ...

library=open_clip. If you found this repository useful, please consider citing. We welcome anyone to submit an issue or send an email if you have any other requests or suggestions. Note that portions ...

We use our own and third-party cookies to personalize your experience and the promotions you see. Our site uses technology that is not supported by your browser, so ...